RLMD · Relmada Therapeutics, Inc. · Webcasts, Transcripts & Audio
$4.21
+0.05 (+1.20%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$449.19M
Shares
106.69M
Volume · Nov 13
1.74M
Avg daily vol (3M)
1.35M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Relmada Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Relmada Therapeutics, Inc. (RLMD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-12
Relmada Therapeutics, Inc. (RLMD) Q3 2026 Earnings Call Transcript
Confident tone
Spectrum Phase III program
NDV-1 durable response
Manufacturing and IND readiness
Diluted EPS
$-0.12
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call
Diluted EPS
$-0.11
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Relmada Therapeutics, Inc. (RLMD) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Confident tone
Intellectual property
Phase 3 registrational program
NDV01 Phase 2 efficacy data
Diluted EPS
$-0.22
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Confident tone
Phase III RESCUE program
NDV-01 clinical data and efficacy
Regulatory and FDA considerations
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Confident tone
NDV-01 phase two data
NMIBC market opportunity
BCG-naive BRIDGE study / off-label potential
Diluted EPS
$-0.30
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Confident tone
NDV-01 Phase II 6-month data
Sepranolone and Prader-Willi syndrome
Pipeline advancement and upcoming trials
Diluted EPS
$-0.30
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript
Confident tone
NDV-01 for non-muscle invasive bladder cancer
Sepranolone for CNS indications
Competitive landscape in NMIBC
Diluted EPS
$-0.58
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call Transcript
Positive tone
REL-1017 Phase 3 program
Reliance II interim analysis
Futility and clinical significance threshold
Diluted EPS
$-0.72
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call Transcript
Positive tone
REL-1017 Phase 3 Program (Reliance II & Relight)
Preplanned Interim Analysis
REL-P11 Psilocybin Program for Metabolic Disease
Diluted EPS
$-0.59
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q1 2024 Earnings Call Transcript
Positive tone
Phase III REL-1017 program execution
Psilocybin modified-release program
Site management and trial oversight
Diluted EPS
$-0.72
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Relmada Therapeutics, Inc. (RLMD) Q4 2023 Earnings Call Transcript
Positive tone
RELIGHT (Study 304) Phase 3 progress
REL-1017 / RELIANCE II enrollment and protocol changes
Modified-release psilocybin preclinical/Phase 1 program
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Relmada Therapeutics, Inc. (RLMD) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.73
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Relmada Therapeutics, Inc. (RLMD) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.84
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Relmada Therapeutics, Inc. (RLMD) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.87
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-23
Relmada Therapeutics, Inc. (RLMD) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Relmada Therapeutics, Inc. (RLMD) Q3 2022 Earnings Call Transcript
Diluted EPS
$-1.31
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q2 2022 Earnings Call Transcript
Diluted EPS
$-1.33
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Relmada Therapeutics, Inc. (RLMD) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-23
Relmada Therapeutics, Inc. (RLMD) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q3 2021 Earnings Call Transcript
Diluted EPS
$-2.44
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q2 2021 Earnings Call Transcript
Diluted EPS
$-1.56
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Date not confirmed
Relmada Therapeutics, Inc. (RLMD) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-23
Relmada Therapeutics, Inc. (RLMD) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–25 of 25 webcasts
Key facts
CIK
1553643
CUSIP
75955J402
13F (30d)
91 filings
78 filers
Visit website
Investor relations